BAT (Cangene Corporation)


Welcome to the PulseAid listing for the BAT drug offered from Cangene Corporation. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.

LABELER NAME / MANUFACTURER: Cangene Corporation
NON-PROPRIETARY NAME: Botulism Antitoxin Heptavalent
SUBSTANCE NAME: EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS:
ROUTE: INTRAVENOUS
DOSAGE FORM: LIQUID
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2013-03-01
END MARKETING DATE: 0000-00-00


BAT PLASMA DERIVATIVE Details:

Item DescriptionBAT from Cangene Corporation
LABELER NAME: Cangene Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 4500; 3300; 3000; 600; 5100; 3000; 600([iU]/10mL; [iU]/10mL; [iU]/10mL; [iU]/10mL; [iU]/10mL; [iU]/10mL; [iU]/10mL)
START MARKETING DATE: 2013-03-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 60492-0075_917691ee-4d8b-468f-8cc5-b64c0688e4ae
PRODUCT NDC: 60492-0075
APPLICATION NUMBER: BLA125462

Other EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2; EQUINE BOTULINUM NEUROTOXIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Cangene CorporationBAT